Interlaboratory variation for NT-proBNP among Swedish laboratories in an external quality program 2011–2021

Objectives: NT-proBNP is frequently used for ruling out heart failure. Different cut-offs are used depending on the clinical context, e.g. an acute or chronic condition. Medical decision limits have been suggested at 125 and 300 ng/L or 400 ng/L in international guidelines. However, there is limited standardization between NT-proBNP methods and using the same blood sample might cause different treatment of patients. Methods: Data from the external quality assessment program for NT-proBNP from Equalis, Sweden, were extracted for the period 2011–2021, and categorized according to manufacturer. Manufacturer median NT-proBNP values were compared to total median values. CV% was calculated for each manufacturer and in comparison to different levels of NT-proBNP. Results: Roche was the most common method, and its median results were closest to the median consensus results. When looking at the total CV at NT-proBNP levels in the range of 0–500 ng/L, the total CV varied from 4 to 27%. During 2019–2021, Siemens (Immulite, Centaur, Atellica) yielded results 16–20% above the consensus median depending on sample level. Similarly, Abbott was 5–7% above, while Roche and Siemens Stratus were 1% respectively 6–10% below the consensus median. Conclusions: The introduction of new manufacturers and methods in 2017 have caused the agreement between manufacturers to decline. This highlights the need for a common calibrator and reference materials, particularly since medical decision limits in guidelines, e.g. European Society of Cardiology 2021, which are mostly based on Roche methods, do not take these method differences into account.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Interlaboratory variation for NT-proBNP among Swedish laboratories in an external quality program 2011–2021 ; volume:61 ; number:9 ; year:2023 ; pages:1643-1651 ; extent:09 ; Clinical chemistry and laboratory medicine ; 61, Heft 9 (2023), 1643-1651 (gesamt 09)

Contributors, Places and Time

• Creator: Lundgren, Morgan ; Ridefelt, Peter ; Karlsson, Mathias ; Norling, Anna ; Larsson, Anders

Further information

• DOI: 10.1515/cclm-2023-0051
• URN: urn:nbn:de:101:1-2023071514043368172504
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 14.08.2025, 10:55 AM CEST